Calumet's Q2 revenue fell to $1.03B as transformation costs mounted. The Montana sale expected in Q3 will reshape the balance sheet and focus. Management sees a H2 ramp.
Calumet Specialty Products (NASDAQ:CLMT) reported a second quarter that laid bare the costs of its ongoing shift. Revenue came in at $1.03 billion, down from $1.1 billion a year earlier. The net loss widened to $42.9 million from $9.3 million in the same quarter of 2023.
The headline numbers reflect a business mid-transition. Calumet is selling its lower-margin Montana/Renewables segment to focus entirely on specialty products and performance brands. That sale, announced in April, is expected to close in the third quarter. Until it does, the company carries costs from a business it no longer prioritizes.
The specialty products segment itself showed the pressure. Gross profit in the division fell to $82.1 million from $108.3 million a year ago, a drop of roughly 24%. The margin compression came from higher feedstock costs and a less favorable product mix, the company said. Calumet's performance brands segment, which includes the Blue Beacon truck wash chain and Royal Purple lubricants, held up better with gross profit of $19.2 million, down only slightly from $20.3 million.
Adjusted EBITDA for the quarter was $63.1 million, down from $83.4 million in the second quarter of 2023. The company maintained its full-year adjusted EBITDA guidance of $275 million to $325 million, a range that implies a significant ramp in the second half.
The balance sheet remains the central concern. Calumet ended the quarter with $58 million in cash and $1.1 billion in total debt. Net leverage stood at roughly 6.5 times trailing twelve-month adjusted EBITDA, high for a specialty chemical company. The Montana sale proceeds, expected to be around $200 million, would bring that down to a more manageable level.
Management framed the quarter as the last messy one before the pure-play structure takes effect. "We are executing on our strategy to become a leading independent specialty products and performance brands company," CEO Steve Mawer said in the release. The market is not fully pricing that thesis yet. CLMT shares trade at roughly 7.5 times the midpoint of adjusted EBITDA guidance, a discount to specialty chemical peers that trade at 10-12 times.
The bull case rests on the second-half ramp. Calumet expects higher seasonal demand for asphalt and specialty solvents, plus the full benefit of cost initiatives that began in the first quarter. The bear case is that the margin compression in specialty products reflects structural pressure, not a one-time feedstock spike. The third quarter will be the first clean read on the standalone business.
The Montana sale closes the structural story. The third quarter will be the first clean read on the standalone business.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.